R&D In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Titan's Spheramine fails in Parkinson's: Titan Pharmaceutical's Parkinson's disease drug Spheramine missed its primary endpoints and key secondary endpoints in a Phase IIb STEPS study, the firm announced July 2. Spheramine, which is injected into the brain to enhance dopamine, was tested in patients not getting sufficient control with oral medication. No difference was seen between the treatment arm and the sham surgery arm after 12 months of follow-up. Titan's partner, Bayer Schering, is halting development of the cell-based therapy